Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Gross Margin: 2009-2025

Historic Gross Margin for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to 46.53%.

  • Cumberland Pharmaceuticals' Gross Margin fell 507.00% to 46.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.54%, marking a year-over-year increase of 628.00%. This contributed to the annual value of 55.05% for FY2024, which is 170.00% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Gross Margin stood at 46.53% for Q3 2025, which was down 23.75% from 61.03% recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Gross Margin peaked at 64.06% during Q1 2021, and registered a low of 46.53% during Q3 2025.
  • Moreover, its 3-year median value for Gross Margin was 53.63% (2023), whereas its average is 54.85%.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Gross Margin tumbled by 1,384bps in 2023 and then surged by 1,276bps in 2025.
  • Cumberland Pharmaceuticals' Gross Margin (Quarterly) stood at 60.26% in 2021, then skyrocketed by 270bps to 62.96% in 2022, then plummeted by 1,384bps to 49.12% in 2023, then surged by 1,042bps to 59.54% in 2024, then tumbled by 507bps to 46.53% in 2025.
  • Its Gross Margin stands at 46.53% for Q3 2025, versus 61.03% for Q2 2025 and 63.87% for Q1 2025.